One of the greatest challenges in oncology is represented by those cancers that do not respond to conventional drug treatments. ViroStatics discovers and develops novel, selective, host cell kinase targeted inhibitors for a multifaceted treatment of most aggressive cancers with high unmet medical need.
Consistent with its mechanism of action, the lead compound VS2-370 is more active against CDK4/6/9 dependent tumors, such as pancreatic cancer, aggressive lymphomas, leukemias, lung cancer and breast cancer.
ViroStatics’ clinical candidate VS2-370, in advanced preclinical development, displays a good druggability profile and some unique features: